Rubius Therapeutics (RUBY) is revealing for the first time Tuesday preclinical data to support efforts to transform red blood cells into new types of drugs that attack cancer.

Before today, Rubius was best known for going public with a $2 billion valuation despite zero drugs in clinical trials. There was also that creative re-imagination of its pipeline chart. The results unveiled Tuesday are still from experiments in test tubes and mice, but for Rubius CEO Pablo Cagnoni, they demonstrate that genetically augmenting red blood cells with molecules and proteins to stimulate the immune system is possible.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy